Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients

Journal of Oncology Pharmacy Practice

Volumn 15, Issue 3, 2009, Pages 175-182

  Harnicar, Stephen ^a   Adel, Nelly ^a   Jurcic, Joseph ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antifungal; Azoles; CYP3A4; Leukemia; Vincristine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; FLUCONAZOLE; POSACONAZOLE; VINCRISTINE; VORICONAZOLE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; ILEUS; INCIDENCE; MALE; MYCOSIS; PERISTALSIS; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; PERISTALSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES; VINCRISTINE;

EID: 69849111376     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208101959     Document Type: Article

References (18)

1. Linker CA, Levitt LJ, O'Donnell M. et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report. Blood 1991; 78(11): 2814-22.
2. Larson RA, Dodge RK, Burns C. et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811. Blood 1995; 85(8): 2025-37.
3. Kantarjian HM, O'Brien S., Smith TL et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia. J Clin Onc 2000; 18(3): 547-61.
4. Weiss M., Maslak P., Feldman E. et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Onc 1996; 14(9): 2480-5.
5. Schauer P., Arlin ZA, Mertelsmann R. et al. Treatment of acute lymphoblastic leukemia in adults: Results of the L-10 and L-10M protocols. J Clin Onc 1983; 1(8): 462-70.
6. McCune JS, Lindley C. Appropriateness of maximum-dose guidelines for vincristine. Am J Health-Syst Pharm 1997; 54: 1755-58.
7. Gubbins PO Mould-active azoles: Pharmacokinetics, drug interactions in neutropenic patients. Curr Opin Infect Dis 2007; 20: 579-86.
8. Flockhart DA Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). (Available at http://medicine.iupui.edu/flockhart/table.htm, accessed 12 November 2007).
9. Cornely OA, Maertens J., Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356(4): 348-59.
10. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-72.
11. Herbrecht R., Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-15.
12. Greenberg RN, Mullane K., van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50(1): 126-33.
13. Ullmann AJ, Cornely OA, Burchardt A. et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-66.
14. Chen S., Wu D., Sun A. et al. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukemia. Am J Hem 2007; 82: 942.
15. Takahashi N., Kameoka Y., Yamanaka Y. et al. Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma. Internal Med 2008; 47: 651-53.
16. Bohme A., Ganser A., Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995; 71(6): 311-2.
17. Frattini M. "Re: Posaconazole prophylaxis." E-mail to the author, 27 August 2008.
18. Murayama N., Imai N., Nakane T. et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new antifungal agent, in human liver microsomes. Biochem Pharmacol 2007; 73(12): 2020-6.